Cantor Stuart L, Hoag Stephen W, Augsburger Larry L
ICON Development Solutions, Ellicott City, MD, USA.
Drug Dev Ind Pharm. 2009 May;35(5):568-82. doi: 10.1080/03639040802459460.
The purpose was to investigate the effectiveness of an ethylcellulose (EC) bead matrix and different film-coating polymers in delaying drug release from compacted multiparticulate systems. Formulations containing theophylline or cimetidine granulated with Eudragit RS 30D were developed and beads were produced by extrusion-spheronization. Drug beads were coated using 15% wt/wt Surelease or Eudragit NE 30D and were evaluated for true density, particle size, and sphericity. Lipid-based placebo beads and drug beads were blended together and compacted on an instrumented Stokes B2 rotary tablet press. Although placebo beads were significantly less spherical, their true density of 1.21 g/cm(3) and size of 855 mum were quite close to Surelease-coated drug beads. Curing improved the crushing strength and friability values for theophylline tablets containing Surelease-coated beads; 5.7 +/- 1.0 kP and 0.26 +/- 0.07%, respectively. Dissolution profiles showed that the EC matrix only provided 3 h of drug release. Although tablets containing Surelease-coated theophylline beads released drug fastest overall (t(44.2%) = 8 h), profiles showed that coating damage was still minimal. Size and density differences indicated a minimal segregation potential during tableting for blends containing Surelease-coated drug beads. Although modified release profiles >8 h were achievable in tablets for both drugs using either coating polymer, Surelease-coated theophylline beads released drug fastest overall. This is likely because of the increased solubility of theophylline and the intrinsic properties of the Surelease films. Furthermore, the lipid-based placebos served as effective cushioning agents by protecting coating integrity of drug beads under a number of different conditions while tableting.
目的是研究乙基纤维素(EC)珠粒基质和不同的薄膜包衣聚合物在延缓压实多颗粒系统中药物释放方面的有效性。开发了含有用Eudragit RS 30D制粒的茶碱或西咪替丁的制剂,并通过挤出滚圆法制备珠粒。使用15%(重量/重量)的Surelease或Eudragit NE 30D对药物珠粒进行包衣,并对其真密度、粒径和球形度进行评估。将脂质基安慰剂珠粒和药物珠粒混合在一起,并在配备仪器的斯托克斯B2旋转压片机上进行压实。尽管安慰剂珠粒的球形度明显较低,但其1.21 g/cm³的真密度和855μm的粒径与Surelease包衣的药物珠粒相当接近。固化提高了含有Surelease包衣珠粒的茶碱片剂的抗压强度和脆碎度值;分别为5.7±1.0 kP和0.26±0.07%。溶出曲线表明,EC基质仅提供3小时的药物释放。尽管含有Surelease包衣茶碱珠粒的片剂总体上药物释放最快(t(44.2%) = 8小时),但曲线表明包衣损伤仍然最小。尺寸和密度差异表明,对于含有Surelease包衣药物珠粒的混合物,压片过程中的分离潜力最小。尽管使用两种包衣聚合物都可以使两种药物的片剂实现>8小时的缓释曲线,但Surelease包衣的茶碱珠粒总体上药物释放最快。这可能是由于茶碱溶解度的增加以及Surelease薄膜的固有特性。此外,脂质基安慰剂在压片的多种不同条件下通过保护药物珠粒的包衣完整性而起到有效的缓冲剂作用。